All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.


Desensitization to Antibiotic Allergies

Thursday, June 27, 2019, 2:00 PM - 3:30 PM CT
Register to attend via Webinar

This activity can also serve as BCIDP recertification credit hours!
Participants who wish to claim BCIDP credit after attending this webinar can purchase the credit online for $75. SIDP members can purchase BCIDP credit at a special member rate of $37.50. Links for purchasing BCIDP recertification credit will be available during the evaluation process after the webinar.


A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) 

 View more SIDPEC Activities

Activity Description

Beta-lactam, sulfa, and fluoroquinolone allergies are the most commonly reported antibiotic allergies. There are conflicting practice habits about the safety of using antibiotics within the same class as the primary allergen. This results in the avoidance of all first line medications for patients labeled as penicillin, sulfa, or fluoroquinolone allergic. This webinar will use five clinical scenarios to explore treatment options for patients with antibiotic allergies. The cases will focus on use of sulfonamide nonantibiotics in patients with sulfa antibiotic allergies, use of ceftriaxone and cefazolin in patients with penicillin allergies, oral amoxicillin/penicillin challenge for patients with penicillin allergies, and fluoroquinolone cross-reactivity.

Learning Objectives

The target audience for this activity includes pharmacists. At the completion of this symposium, the participant will be able to:

  • Discuss physiology of hypersensitivity reactions.
  • Identify the mechanisms of cross-reactivity between and among sulfa containing medications, beta-lactams, and fluoroquinolones.
  • Interpret the available clinical evidence measuring risk of hypersensitivity.
  • Explain how to create antimicrobial regimens for patients with antimicrobial allergies.


Meghan Jeffres, PharmD, BCIDP
Assistant Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy

CE Accreditation


This activity is jointly provided by ProCE, Inc. and the Society of Infectious Diseases Pharmacists. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-19-225-L01-P has been assigned to this live knowledge-based activity (initial release date 6-27-2019). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation no later than July 26, 2019 to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.


The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation.


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Jeffres has no relevant commercial or financial relationships to disclose.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider or SIDP. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.


This activity is provided by ProCE, Inc. and SIDP.


Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.